Immunotherapy for the Treatment of Non-Small Cell Lung Cancer

Publication Date: July 17, 2018

Diagnosis for NSCLC

Diagnosis for NSCLC

The analysis of PD-L1 expression by an immunohistochemistry (IHC)-based test to determine PD-L1 expression levels is recommended for all patients with newly diagnosed advanced NSCLC.
  • Prior to initiation of immunotherapy, tests recommended by the majority of the Task Force included computerized tomography (CT) of the chest, abdomen, and pelvis and thyroid function tests (in addition to routine lab tests).

PD-L1 testing is recommended in newly diagnosed patients with metastatic disease, including those tested for EGFR/ALK/ROS1 mutations whose results are awaited.
678

Table 1. PD-L1 Assay Characteristics and Performance in NSCLC

...L1 Assay Characteristics and Performance in...

Treatment for NSCLC

...Treatment fo...

Figure 1. Advanced/Metastatic NSCLC Treatment Algorithm

...1. Advanced/Metastatic NSCLC Treatment Algorithm...

...testing for all newly diagnosed patient...


...line pembrolizumab monotherapy should be use...


...ients with squamous histology and PD-L1...


For patients with non-squamous, advanced NSCLC...


...zumab, nivolumab, or pembrolizumab (TPS ...


...with non-squamous, advanced NSCLC with PD-L1 T...


...lizumab is recommended first-line in patient...


...ould be used in stage III patients who have n...


Monitoring for NSCLC

...Monitori...

...and Monitoring Radiographic Respon...


...nizing, Monitoring and Managing Treatment-R...


...2. FDA-approved Programmed Cell Deat...